| For: | Mikhail N. Place of sodium-glucose co-transporter type 2 inhibitors for treatment of type 2 diabetes. World J Diabetes 2014; 5(6): 854-859 [PMID: 25512787 DOI: 10.4239/wjd.v5.i6.854] |
|---|---|
| URL: | https://www.wjgnet.com/1948-9358/full/v5/i6/854.htm |
| Number | Citing Articles |
| 1 |
Ramachandran Vinayagam, Muthukumaran Jayachandran, Baojun Xu. Antidiabetic Effects of Simple Phenolic Acids: A Comprehensive Review. Phytotherapy Research 2016; 30(2) doi: 10.1002/ptr.5528
|
| 2 |
Carmen Gloria Aylwin H.. NUEVOS FÁRMACOS EN DIABETES MELLITUS. Revista Médica Clínica Las Condes 2016; 27(2) doi: 10.1016/j.rmclc.2016.04.013
|
| 3 |
Sebastian Niezen, Humberto Diaz del Castillo, Lumen A. Mendez Castaner, Alessia Fornoni. Safety and efficacy of antihyperglycaemic agents in diabetic kidney disease. Endocrinology, Diabetes & Metabolism 2019; 2(3) doi: 10.1002/edm2.72
|
| 4 |
Sara Castro-Barquero, Mana Shahbaz, Ramon Estruch, Rosa Casas. Comprehensive Foodomics. 2021; doi: 10.1016/B978-0-08-100596-5.22894-1
|
| 5 |
Chieh-Sen Chuang, Chew-Teng Kor, Shu-Yi Wang, Ying-Lin Hsu. Efficacy and safety of SGLT2 inhibitors in elderly patients with type 2 diabetes. Annals of Medicine 2026; 58(1) doi: 10.1080/07853890.2026.2696636
|
| 6 |
Sho-ichi Yamagishi, Takanori Matsui. Protective Role of Sodium–Glucose Co-Transporter 2 Inhibition Against Vascular Complications in Diabetes. Rejuvenation Research 2016; 19(2) doi: 10.1089/rej.2015.1738
|
| 7 |
Yi-Hsuan Lin, Yu-Yao Huang, Sheng-Hwu Hsieh, Jui-Hung Sun, Szu-Tah Chen, Chia-Hung Lin. Renal and Glucose-Lowering Effects of Empagliflozin and Dapagliflozin in Different Chronic Kidney Disease Stages. Frontiers in Endocrinology 2019; 10 doi: 10.3389/fendo.2019.00820
|
| 8 |
Blythe D. Shepard, Carolyn M. Ecelbarger. Sodium Glucose Transporter, Type 2 (SGLT2) Inhibitors (SGLT2i) and Glucagon-Like Peptide 1-Receptor Agonists: Newer Therapies in Whole-Body Glucose Stabilization. Seminars in Nephrology 2021; 41(4) doi: 10.1016/j.semnephrol.2021.06.005
|
| 9 |
Edmund Cheung So, Ping-Yen Liu, Sheng-Nan Wu. Effectiveness in the inhibition of dapagliflozin and canagliflozin on M-type K+ current and α-methylglucoside-induced current in pituitary tumor (GH3) and pheochromocytoma PC12 cells. European Journal of Pharmacology 2020; 879 doi: 10.1016/j.ejphar.2020.173141
|
| 10 |
Rashika Bansal, Elaine Cochran, Megan Startzell, Rebecca J. Brown. Clinical Effects of Sodium-Glucose Transporter Type 2 Inhibitors in Patients With Partial Lipodystrophy. Endocrine Practice 2022; 28(6) doi: 10.1016/j.eprac.2022.03.006
|
| 11 |
Sarah Edwards, Christine Lam, Lindsay Thomas. Evaluation of the Safety and Tolerability of Sodium-Glucose Co-transporter 2 Inhibitors in the Older Population: A Systematic Review. The Senior Care Pharmacist 2023; 38(7) doi: 10.4140/TCP.n.2023.276
|
| 12 |
Nareen Krishna Polavarapu, Ravindra Kale, Bipin Sethi, R. K. Sahay, Uday Phadke, Santosh Ramakrishnan, Amey Mane, Suyog Mehta, Snehal Shah. Effect of Gliclazide or Gliclazide plus Metformin Combination on Glycemic Control in Patients with T2DM in India: A Real-World, Retrospective, Longitudinal, Observational Study from Electronic Medical Records. Drugs - Real World Outcomes 2020; 7(4) doi: 10.1007/s40801-020-00206-7
|
| 13 |
Sherrie Khadanga, Kaitlyn Barrett, Kelsey H. Sheahan, Patrick D. Savage. Novel Therapeutics for Type 2 Diabetes, Obesity, and Heart Failure. Journal of Cardiopulmonary Rehabilitation and Prevention 2023; 43(1) doi: 10.1097/HCR.0000000000000761
|
| 14 |
Irina Balan, V Lakshmi N Priyanka Ganapathiraju, Sudha Dirisanala, Shafaq Taj, Pratikkumar Vekaria. Case Report: Euglycemic diabetic ketoacidosis led by empagliflozin: A case report and literature review. F1000Research 2022; 11 doi: 10.12688/f1000research.127382.1
|
| 15 |
Abhiroop Chakravarty, Mohini Rastogi, Praveen Dhankhar, Kelly F. Bell. Comparison of costs and outcomes of dapagliflozin with other glucose-lowering therapy classes added to metformin using a short-term cost-effectiveness model in the US setting. Journal of Medical Economics 2018; 21(5) doi: 10.1080/13696998.2018.1434182
|
| 16 |
Nur Aisyah Zainordin, Sharifah Faradilla Wan Muhamad Hatta, Fatimah Zaherah Mohamed Shah, Thuhairah Abdul Rahman, Nurhuda Ismail, Zaliha Ismail, Rohana Abdul Ghani. Effects of Dapagliflozin on Endothelial Dysfunction in Type 2 Diabetes With Established Ischemic Heart Disease (EDIFIED). Journal of the Endocrine Society 2020; 4(1) doi: 10.1210/jendso/bvz017
|
| 17 |
Rizwana Parveen, Nidhi Bharal Agarwal, Neelam Kaushal, Ghanshyam Mali, Sheikh Raisuddin. Efficacy and safety of canagliflozin in type 2 diabetes mellitus: systematic review of randomized controlled trials. Expert Opinion on Pharmacotherapy 2016; 17(1) doi: 10.1517/14656566.2016.1109629
|
| 18 |
Lili Sun, Guiling Liu, Baozhong Liang, Houmei You. Dapagliflozin as an adjunct to insulin improves glycemic control, weight, and lipid profile with a superior safety profile in type 2 diabetes: a randomized trial. Clinics 2026; 81 doi: 10.1016/j.clinsp.2026.101116
|
| 19 |
Hong Ding, Kevin Ye, Chris R Triggle. Impact of currently used anti-diabetic drugs on myoendothelial communication. Current Opinion in Pharmacology 2019; 45 doi: 10.1016/j.coph.2018.11.002
|
| 20 |
Tatjana Stefanović, Srećko Bosić, Jelena Vekić, Vesna Spasojević-Kalimanovska, Vesna Todorović, Marina Pijanović, Aleksandra Zeljković, Aleksandra Stefanović, Zorana Jelić-Ivanović. Significance of glycosylated haemoglobin determination for the assessment of lower-extremity amputation risk in patients with diabetic foot. Arhiv za farmaciju 2019; 69(2) doi: 10.5937/arhfarm1902051X
|
| 21 |
Vaishnavi Sivaji, Prasanna Raju, Soundarrajan Marimuthu, Subash Sundar. Familial renal glycosuria identified in an Indian family. BMJ Case Reports 2024; 17(9) doi: 10.1136/bcr-2023-258408
|
| 22 |
Gwanpyo Koh, Hyounjung Chin. Interpretation of cardiovascular outcome trials results of new antidiabetic agents. Journal of Medicine and Life Science 2024; 21(3) doi: 10.22730/jmls.2024.21.3.62
|
| 23 |
Jeanna Sewell, Rebecca Johnson. Managing Diabetes. Physician Assistant Clinics 2023; 8(2) doi: 10.1016/j.cpha.2022.10.007
|
| 24 |
Munehisa Bekki, Nobuhiro Tahara, Atsuko Tahara, Sachiyo Igata, Akihiro Honda, Yoichi Sugiyama, Tomohisa Nakamura, Jiahui Sun, Yuki Kumashiro, Takanori Matsui, Yoshihiro Fukumoto, Sho-ichi Yamagishi. Switching Dipeptidyl Peptidase-4 Inhibitors to Tofogliflozin, a Selective Inhibitor of Sodium-Glucose Cotransporter 2 Improve Arterial Stiffness Evaluated by Cardio-Ankle Vascular Index in Patients with Type 2 Diabetes: A Pilot Study. Current Vascular Pharmacology 2019; 17(4) doi: 10.2174/1570161116666180515154555
|
| 25 |
Markéta Kubíčková. Specifics of diabetes in old age. Interní medicína pro praxi 2019; 21(4) doi: 10.36290/int.2019.034
|
| 26 |
Giuseppe Palmiero, Arturo Cesaro, Raffaele Galiero, Giuseppe Loffredo, Alfredo Caturano, Erica Vetrano, Luca Rinaldi, Teresa Salvatore, Roberto Ruggiero, Maria Rosaria Di Palo, Celestino Sardu, Raffaele Marfella, Giuseppe Limongelli, Paolo Calabrò, Ferdinando Carlo Sasso. Impact of gliflozins on cardiac remodeling in patients with type 2 diabetes mellitus & reduced ejection fraction heart failure: A pilot prospective study. GLISCAR study. Diabetes Research and Clinical Practice 2023; 200 doi: 10.1016/j.diabres.2023.110686
|
| 27 |
Lisa La, Luigi Maione. Effets cardio- et néphroprotecteurs des inhibiteurs du SGLT2. La Revue de Médecine Interne 2024; 45(6) doi: 10.1016/j.revmed.2024.05.026
|
| 28 |
Raktim Kumar Ghosh, Dhrubajyoti Bandyopadhyay, Adrija Hajra, Monodeep Biswas, Anjan Gupta. Cardiovascular outcomes of sodium-glucose cotransporter 2 inhibitors: A comprehensive review of clinical and preclinical studies. International Journal of Cardiology 2016; 212 doi: 10.1016/j.ijcard.2016.02.134
|
| 29 |
Behina Forouzanmehr, Amir Hossein Hedayati, Emad Gholami, Mohammad Amin Hemmati, Mina Maleki, Alexandra E. Butler, Tannaz Jamialahmadi, Prashant Kesharwani, Habib Yaribeygi, Amirhossein Sahebkar. Sodium-glucose cotransporter 2 inhibitors and renin-angiotensin-aldosterone system, possible cellular interactions and benefits. Cellular Signalling 2024; 122 doi: 10.1016/j.cellsig.2024.111335
|
| 30 |
W. Timothy Garvey, Guillermo E. Umpierrez, Julia P. Dunn, Anita Y. M. Kwan, Oralee J. Varnado, Manige Konig, Joshua A. Levine. Examining the evidence for weight management in individuals with type 2 diabetes. Diabetes, Obesity and Metabolism 2022; 24(8) doi: 10.1111/dom.14764
|
| 31 |
Lei Huang, Bei Cao, Yan Geng, Xiaoli Zhou, Yuanxun Yang, Tingting Ma, Hui Lin, Zhijiang Huang, Lang Zhuo, Juan Li. A randomized double-blind phase Ib clinical trial of SY-009 in patients with type 2 diabetes mellitus. European Journal of Pharmaceutical Sciences 2024; 192 doi: 10.1016/j.ejps.2023.106644
|
| 32 |
Nasser Mikhail. Remogliflozin etabonate: a novel SGLT2 inhibitor for treatment of diabetes mellitus. Expert Opinion on Investigational Drugs 2015; 24(10) doi: 10.1517/13543784.2015.1061501
|
| 33 |
Nobutaka Nakamura, Takanori Matsui, Yuji Ishibashi, Sho-ichi Yamagishi. Insulin stimulates SGLT2-mediated tubular glucose absorption via oxidative stress generation. Diabetology & Metabolic Syndrome 2015; 7(1) doi: 10.1186/s13098-015-0044-1
|
| 34 |
Fernando B. Bonanni, Patrick Fei, Laura L. Fitzpatrick. Normoglycemic ketoacidosis in a postoperative gastric bypass patient taking canagliflozin. Surgery for Obesity and Related Diseases 2016; 12(1) doi: 10.1016/j.soard.2015.08.502
|
| 35 |
Konstantinos P. Imprialos, Pantelis A. Sarafidis, Asterios I. Karagiannis. Sodium–glucose cotransporter-2 inhibitors and blood pressure decrease. Journal of Hypertension 2015; 33(11) doi: 10.1097/HJH.0000000000000719
|
| 36 |
Teresa Salvatore, Alfredo Caturano, Raffaele Galiero, Anna Di Martino, Gaetana Albanese, Erica Vetrano, Celestino Sardu, Raffaele Marfella, Luca Rinaldi, Ferdinando Carlo Sasso. Cardiovascular Benefits from Gliflozins: Effects on Endothelial Function. Biomedicines 2021; 9(10) doi: 10.3390/biomedicines9101356
|
| 37 |
Elizabeth Mary Lamos, Maka Hedrington, Stephen N Davis. An update on the safety and efficacy of oral antidiabetic drugs: DPP-4 inhibitors and SGLT-2 inhibitors. Expert Opinion on Drug Safety 2019; 18(8) doi: 10.1080/14740338.2019.1626823
|
| 38 |
Pattanaik S.R. EFFICACY OF CANAGLIFLOZIN AS AN ADD-ON TO TRIPLE DRUG TREATMENT WITH GLIMEPIRIDE, METFORMIN AND TENELIGLIPTIN. Journal of Evidence Based Medicine and Healthcare 2018; 5(27) doi: 10.18410/jebmh/2018/425
|
| 39 |
Abhinav Kanwal, Navjot Kanwar, Sanjay Bharati, Prateek Srivastava, Shailendra P. Singh, Salomon Amar. Exploring New Drug Targets for Type 2 Diabetes: Success, Challenges and Opportunities. Biomedicines 2022; 10(2) doi: 10.3390/biomedicines10020331
|
| 40 |
Awadhesh Kumar Singh, Ritu Singh. Dipeptidyl peptidase-4 inhibitors as add-on therapy to insulin: rationale and evidences. Expert Review of Clinical Pharmacology 2016; 9(4) doi: 10.1586/17512433.2016.1130621
|
| 41 |
Angus Gill, Stephen P. Gray, Karin A. Jandeleit-Dahm, Anna M.D. Watson. SGLT-2 Inhibition: Novel Therapeutics for Reno-and Cardioprotection in Diabetes Mellitus. Current Diabetes Reviews 2019; 15(5) doi: 10.2174/1573399814666180417121246
|
| 42 |
Mohini Aras, Beverly G. Tchang, Joy Pape. Obesity and Diabetes. Nursing Clinics of North America 2021; 56(4) doi: 10.1016/j.cnur.2021.07.008
|